Difficulty: Intermediate to Advanced | Prerequisites: Parts 1 and 2 of these notes (intercellular communication, chemical messenger types and transport).
Once a chemical messenger reaches its target cell, something has to happen inside the cell. That "something" is signal transduction: the conversion of an extracellular signal into an intracellular response. This is where messenger type, receptor type, and cellular outcome all come together. The topic also introduces receptor regulation (up-regulation, down-regulation) and pharmacological concepts (agonists, antagonists) that are tested heavily and carry straight into pharmacology and clinical medicine. You need to be comfortable with the lipophilic/lipophobic distinction and receptor locations from Parts 1 and 2 before starting here.
Hydrophilic messengers bind membrane receptors (channel-linked, enzyme-linked, or G protein-coupled) and trigger fast, short-lived responses via second messengers. Lipophilic messengers cross the membrane, bind intracellular receptors, and alter gene transcription for slower but longer-lasting effects. Signal amplification means one receptor activation can produce millions of downstream molecular events.
Signal transduction
The process by which a chemical messenger binding to a receptor triggers a cascade of intracellular events, ultimately changing cell behaviour. In simple terms, it is how a signal on the outside of the cell gets translated into action on the inside.
Ligand
Any molecule that binds specifically to a receptor. Hormones, neurotransmitters, drugs, and toxins can all act as ligands.
Channel-linked receptor (ligand-gated ion channel)
A membrane receptor that opens or closes an ion channel in direct response to ligand binding. This produces the fastest type of cellular response (milliseconds) by changing the cell's membrane potential.
Enzyme-linked receptor
A membrane receptor with intrinsic enzymatic activity (or that directly activates an associated enzyme) upon ligand binding. Receptor tyrosine kinases are the most commonly tested example, triggering phosphorylation cascades.
G protein-coupled receptor (GPCR)
A membrane receptor that, when activated, stimulates an associated G protein to exchange GDP for GTP, which then activates or inhibits downstream effector enzymes to produce second messengers. GPCRs are the largest family of membrane receptors and the target of roughly a third of all approved drugs.
Second messenger
A small intracellular signalling molecule produced in response to receptor activation. Second messengers relay and amplify the signal inside the cell. The main ones are cAMP, cGMP, DAG, IP3, and calcium ions.
cAMP (cyclic adenosine monophosphate)
Produced by adenylate cyclase when a stimulatory G protein is activated. cAMP activates protein kinase A (PKA), which phosphorylates target proteins to change cell behaviour.
cGMP (cyclic guanosine monophosphate)
Produced by guanylate cyclase. Activates protein kinase G (PKG). Involved in smooth muscle relaxation and vision.
DAG (diacylglycerol)
Generated from PIP2 in the membrane. Activates protein kinase C (PKC).
IP3 (inositol trisphosphate)
Also generated from PIP2. Triggers the release of calcium ions from the endoplasmic reticulum into the cytosol.
Calcium ions (Ca2+)
Act as secondary messengers once released from intracellular stores. Calcium binds calmodulin and other proteins, influencing enzymes, contraction, secretion, and gene expression.
PIP2 (phosphatidylinositol 4,5-bisphosphate)
A membrane phospholipid that is cleaved by phospholipase C into DAG and IP3 when certain GPCRs are activated.
Signal amplification
The principle that each step in a signalling cascade multiplies the number of activated molecules, so one receptor event can produce millions of downstream molecular changes. Think of it as a chain reaction where each link activates many copies of the next.
Specificity (receptor)
The ability of a receptor to bind only certain ligands. Different receptor subtypes (e.g. alpha vs. beta adrenergic) respond to the same messenger but produce different cellular effects depending on the tissue.
Affinity (receptor)
A measure of how tightly a ligand binds to its receptor. Higher affinity means the receptor responds to lower concentrations of the messenger.
Up-regulation
An increase in the number of receptors on a cell's surface in response to chronically low ligand levels. The cell becomes more sensitive to the messenger.
Down-regulation
A decrease in receptor numbers in response to chronically high ligand levels. The cell becomes less sensitive. In simple terms, the cell is turning down the volume because the signal is too loud.
Agonist
A ligand that binds a receptor and activates it, producing a biological response. The messenger itself is the natural agonist; drugs can mimic this.
Antagonist
A ligand that binds a receptor without activating it, blocking the natural agonist from binding. In simple terms, it occupies the parking space so the real car cannot pull in.
Hormone response element (HRE)
A specific DNA sequence in a gene's promoter region where a ligand-receptor complex (typically a steroid or thyroid hormone bound to its intracellular receptor) binds to regulate transcription.
Phosphodiesterase
The enzyme that breaks down cyclic nucleotides (cAMP, cGMP), terminating the second messenger signal. Caffeine inhibits cAMP phosphodiesterase.
Hydrophilic messengers cannot enter the cell, so they rely on three types of membrane receptor to transmit their signal.
Channel-linked receptors (ligand-gated ion channels)
Ligand binding directly opens or closes an ion channel.
Ions (Na+, K+, Ca2+, Cl-) flow across the membrane, changing the membrane potential.
Produces the fastest response (milliseconds).
Example: neurotransmitter-gated channels at synapses (e.g. nicotinic acetylcholine receptors).
Enzyme-linked receptors
Ligand binding activates enzymatic activity built into the receptor or an associated enzyme.
Most commonly tested: receptor tyrosine kinases, which phosphorylate intracellular proteins and trigger signalling cascades.
Response time: seconds to minutes.
G protein-coupled receptors (GPCRs)
The largest and most diverse class of membrane receptor.
Ligand binding causes the associated G protein to exchange GDP for GTP, activating it.
The active G protein then stimulates (or inhibits) an effector enzyme (e.g. adenylate cyclase, phospholipase C).
This produces second messengers (cAMP, DAG, IP3, calcium) that amplify the signal inside the cell.
GPCR activation is the main driver of second messenger production.
cAMP pathway
GPCR activates a stimulatory G protein (Gs).
Gs activates adenylate cyclase.
Adenylate cyclase converts ATP to cAMP.
cAMP activates protein kinase A (PKA).
PKA phosphorylates target proteins, changing their activity.
IP3/DAG pathway
GPCR activates a G protein that stimulates phospholipase C.
Phospholipase C cleaves PIP2 (a membrane phospholipid) into IP3 and DAG.
IP3 triggers calcium release from the endoplasmic reticulum.
DAG activates protein kinase C (PKC).
Calcium ions act as secondary messengers themselves, binding calmodulin and other effectors.
cGMP pathway
Produced by guanylate cyclase.
Activates protein kinase G (PKG).
Important in smooth muscle relaxation and phototransduction in the retina.
This is one of the most important concepts in signal transduction.
One activated receptor can activate multiple G proteins.
Each G protein activates one adenylate cyclase molecule.
Each adenylate cyclase produces hundreds of cAMP molecules.
Each cAMP molecule activates a protein kinase A.
Each protein kinase A phosphorylates many target proteins.
The net result: one ligand-receptor event can lead to the phosphorylation of millions of proteins.
This cascade architecture is why even tiny concentrations of hormones can produce large physiological effects.
Lipophilic messengers (steroids, thyroid hormones) bypass the membrane entirely.
The messenger diffuses through the plasma membrane.
It binds an intracellular receptor in the cytosol or nucleus.
The ligand-receptor complex translocates to the nucleus (if not already there).
It binds to a hormone response element (HRE) on DNA.
This modulates gene transcription: increasing or decreasing the synthesis of specific proteins.
The response is slower (hours) but longer-lasting than membrane receptor pathways, because it changes which proteins the cell is producing.
Specificity
Receptors bind only certain ligands.
Different subtypes of the same receptor family can produce different effects. For example, alpha-adrenergic receptors cause vasoconstriction while beta-adrenergic receptors increase heart rate.
Affinity
Describes binding strength.
A high-affinity receptor responds to very low messenger concentrations.
Receptor regulation
Up-regulation: the cell increases receptor numbers when ligand levels are chronically low, boosting sensitivity.
Down-regulation: the cell decreases receptor numbers when ligand levels are chronically high, reducing sensitivity. This is one mechanism behind drug tolerance.
Agonists bind to a receptor and activate it, producing the same type of response as the natural ligand.
Antagonists bind to a receptor without activating it, blocking the natural ligand from binding and preventing its effect.
Clinical example: beta-blockers
Beta-blockers (e.g. propranolol) are antagonists of beta-adrenergic receptors.
They prevent epinephrine and norepinephrine from increasing heart rate and contractility.
Used clinically to lower blood pressure and manage certain cardiac arrhythmias.
These two systems represent the body's main strategies for long-distance signalling.
Nervous system
Signal type: neurotransmitters.
Speed: fast (milliseconds).
Duration: short-lived.
Mechanism: modulation of ion channels.
Endocrine system
Signal type: hormones.
Speed: slow (seconds to hours).
Duration: long-lasting.
Mechanism: protein synthesis and gene regulation.
Both systems often work together. The sympathetic nervous system, for instance, uses norepinephrine at nerve endings (neurotransmitter) while simultaneously triggering epinephrine release from the adrenal medulla (hormone) for a broader, sustained response.
Histamine and antihistamines
Histamine is a paracrine that increases blood flow and capillary permeability during inflammation.
Antihistamines block histamine receptors, reducing allergic symptoms (sneezing, itching, swelling).
Side effect: older antihistamines cross the blood-brain barrier and block H1 receptors in the brain, causing drowsiness.
Aspirin and COX inhibitors
Aspirin non-selectively inhibits COX, reducing both inflammatory and protective prostaglandins.
COX-2 inhibitors selectively target the inflammatory isoform, reducing GI side effects.
Caffeine and cAMP
Caffeine inhibits cAMP phosphodiesterase, the enzyme that breaks down cAMP.
cAMP levels stay elevated, prolonging and amplifying cellular responses.
This produces increased alertness, elevated heart rate, and, at higher doses, shakiness and hyperactivity.
Beta-blockers are one of the most widely prescribed drug classes in cardiology, and their mechanism is a direct application of the agonist/antagonist concept covered here. Understanding signal amplification explains why hormone disorders can have such dramatic effects from small changes in hormone concentration, for instance how a slight excess of thyroid hormone (hyperthyroidism) can cause weight loss, rapid heart rate, and anxiety.
Students often confuse the first messenger with the second messenger. The first messenger is the extracellular ligand (e.g. the hormone). The second messenger is the intracellular molecule produced after receptor activation (e.g. cAMP).
GPCRs do not have enzymatic activity themselves. They activate a G protein, which then activates an effector enzyme. Enzyme-linked receptors (like receptor tyrosine kinases) are the ones with built-in enzymatic activity.
Down-regulation does not mean the receptor is broken. The cell is actively reducing its sensitivity as an adaptive response to prolonged high ligand levels. The receptors are internalised or degraded on purpose.
Signal amplification does not mean the signal gets "louder" at the receptor. It means each downstream step produces more activated molecules than the step before, so the effect snowballs inside the cell.
⚠️ You will almost certainly need to trace a GPCR signalling pathway from ligand binding through G protein activation, second messenger production, kinase activation, and cellular response.
⚠️ Know the five main second messengers (cAMP, cGMP, DAG, IP3, calcium) and which enzyme or pathway produces each.
⚠️ Signal amplification, specifically the cascade from one receptor to millions of phosphorylated proteins, is a favourite exam topic.
⚠️ Expect at least one question distinguishing intracellular receptor signalling (slow, gene transcription) from membrane receptor signalling (fast, enzyme/channel modulation).
⚠️ Up-regulation vs. down-regulation and agonist vs. antagonist are common multiple-choice targets. Know the definitions and a clinical example of each.
⚠️ The nervous vs. endocrine comparison table (signal type, speed, duration, mechanism) is high-yield for short-answer or matching questions.
True or False: G protein-coupled receptors directly phosphorylate target proteins.
False. GPCRs activate G proteins, which then activate effector enzymes that produce second messengers. It is enzyme-linked receptors (e.g. receptor tyrosine kinases) that directly phosphorylate targets.
Fill in the blank: The second messenger cAMP is produced by the enzyme __________ and broken down by the enzyme __________.
Adenylate cyclase; phosphodiesterase.
True or False: Intracellular receptor signalling produces faster responses than membrane receptor signalling.
False. Intracellular receptor signalling (gene transcription changes) is slower but longer-lasting. Membrane receptor signalling (ion channels, second messengers) is faster.
Fill in the blank: A drug that binds a receptor without activating it and blocks the natural ligand is called a(n) __________.
Antagonist.
True or False: Up-regulation makes a cell less sensitive to a messenger.
False. Up-regulation increases receptor numbers, making the cell more sensitive.
Q: Describe the signal transduction pathway that begins when epinephrine binds a beta-adrenergic receptor on a heart muscle cell.
A: Epinephrine binds the beta-adrenergic receptor (a GPCR). This activates a stimulatory G protein (Gs), which activates adenylate cyclase. Adenylate cyclase converts ATP to cAMP. cAMP activates protein kinase A, which phosphorylates target proteins that increase heart rate and contractility.
Q: Why do lipophilic messenger responses take longer to develop than hydrophilic messenger responses?
A: Lipophilic messengers bind intracellular receptors and alter gene transcription, which requires time for mRNA to be produced and translated into new proteins. Hydrophilic messengers activate membrane receptors that change existing protein activity or ion flow within seconds to minutes.
Q: Explain how caffeine increases alertness in terms of second messenger signalling.
A: Caffeine inhibits cAMP phosphodiesterase, the enzyme responsible for breaking down cAMP. This causes cAMP to accumulate inside cells, prolonging and amplifying the effects of signalling pathways that promote alertness and cellular activity.
Q: A patient takes propranolol (a beta-blocker). Explain why this lowers blood pressure using the concepts of agonists and antagonists.
A: Propranolol is an antagonist of beta-adrenergic receptors. It binds the receptor without activating it, blocking epinephrine and norepinephrine (the natural agonists) from binding. This prevents their effects on the heart (increased rate and contractility), resulting in lower cardiac output and reduced blood pressure.
Q: Distinguish between up-regulation and down-regulation. Give one example of when each might occur.
A: Up-regulation is an increase in receptor numbers in response to chronically low ligand levels, making the cell more sensitive. Example: a cell exposed to very low hormone levels for an extended period increases its receptors to capture more of the scarce signal. Down-regulation is a decrease in receptor numbers in response to chronically high ligand levels, making the cell less sensitive. Example: prolonged high insulin levels in type 2 diabetes lead to insulin receptor down-regulation, contributing to insulin resistance.
Signal transduction pathways covered here feed directly into the endocrine system (hormone action at target cells), the nervous system (synaptic transmission and neurotransmitter receptors), muscle physiology (calcium signalling in contraction), and pharmacology (drug design around agonists, antagonists, and second messenger pathways). The nervous vs. endocrine comparison will reappear in every organ system unit, since most organs receive both neural and hormonal regulation.
signal transduction, cell signalling pathways, membrane receptors, ligand-gated ion channels, channel-linked receptors, enzyme-linked receptors, receptor tyrosine kinase, G protein-coupled receptors, GPCRs, G proteins, second messengers, cAMP, cyclic AMP, adenylate cyclase, protein kinase A, PKA, cGMP, guanylate cyclase, protein kinase G, PKG, DAG, diacylglycerol, IP3, inositol trisphosphate, PIP2, calcium signalling, calmodulin, phospholipase C, signal amplification, cascade, receptor specificity, receptor affinity, up-regulation, down-regulation, agonist, antagonist, beta-blockers, propranolol, hormone response elements, HRE, intracellular receptors, nuclear receptors, gene transcription, nervous system vs endocrine system, histamine, antihistamines, aspirin, COX inhibitors, caffeine, phosphodiesterase, anatomy and physiology, A&P study notes